Traders should monitor the DENALI Part 2 topline data by year-end 2026 as a key catalyst; the current cash runway provides buffer, but future dilution risk remains if additional funding is needed post-2027.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 27 $2.10entry
- T+1 · 8mo ago +1.90%α +2.26% · $2.14
- T+5 · 8mo ago +28.10%α +24.23% · $2.69
- T+20 · 7mo ago +102.38%α +89.64% · $4.25
- T+60 · 5mo ago +81.19%α +65.12% · $3.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zentalis Pharmaceuticals reported its 2025 financial results, highlighting a significant reduction in R&D and G&A expenses, with $245.9 million in cash providing a runway into late 2027. The company remains on track for key 2026 milestones, including dose confirmation in 1H 2026 and a topline readout from the DENALI Part 2 trial by year-end, which could support accelerated FDA approval of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities totaled $245.9 million as of December 31, 2025, sufficient to fund operations into late 2027.
- R&D expenses decreased to $107.3 million in 2025 from $167.8 million in 2024, driven by lower clinical, lab, manufacturing, and personnel costs.
- G&A expenses dropped to $37.7 million in 2025 from $87.1 million in 2024, largely due to a $47.1 million reduction in personnel expenses, including $40.8 million in non-cash stock-based compensation.
- No revenue was recorded in 2025, compared to $67.4 million in licensing revenue in 2024 from a prior collaboration.
- DENALI Part 2a enrollment completed; dose confirmation expected in 1H 2026, with topline data from Part 2 expected by end of 2026.
- ASPENOVA Phase 3 trial design aligned with FDA; initiation expected in 1H 2026.
Financial Impact
Operating expenses reduced by $105.8 million YoY, improving cash preservation. However, revenue dropped to $0 in 2025 from $67.4 million in 2024.
Risk Factors
- No revenue in 2025; future depends entirely on azenosertib's clinical and regulatory success.
- Prior revenue was non-recurring (licensing), making current business model unproven.
- Clinical trial delays or negative data could significantly impact valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263392 |
Track record
18 reports on ZNTL
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers